Will This Cancer Metastasize: Groundbreaking research reveals that a tumor’s metastatic potential may be predicted by analyzing cancer cell “stickiness” – the molecular adhesion properties that determine whether cells:
✔ Break away from primary tumors
✔ Survive in circulation
✔ Anchor to distant organs
At Travel For Med, we connect patients with leading oncology centers utilizing cutting-edge adhesion profiling to predict and prevent metastatic spread.
How Cancer Cell Stickiness Controls Metastasis
The Metastatic Cascade & Adhesion Checkpoints
-
Detachment (Loss of E-cadherin)
-
Intravasation (Integrin-mediated vessel entry)
-
Circulation Survival (Platelet cloaking)
-
Extravasation (Selectin “rolling” and arrest)
-
Colonization (Chemokine-guided nesting)
Key Adhesion Molecules Under Study
| Molecule | Role | Therapeutic Target |
|---|---|---|
| E-cadherin | Epithelial “glue” | Yes (Restorers) |
| Integrins | Matrix attachment | Cilengitide trials |
| Selectins | Vascular docking | Rivipansel trials |
| CD44 | Hyaluronan binding | Antibody blockade |
Diagnostic Tests Measuring Cancer Stickiness
1. Circulating Tumor Cell (CTC) Adhesion Assays
-
Microfluidic chips simulate vascular walls
-
Measure CTC arrest under flow conditions
-
Predictive value: 82% accuracy for metastasis
2. Immunohistochemistry Adhesion Profiles
-
Tumor biopsy analysis of:
-
E-cadherin expression
-
Integrin αvβ3 levels
-
Selectin ligand presence
-
3. Liquid Biopsy Adhesion Signatures
✔ Detect shed adhesion proteins in blood
✔ Cluster analysis of CTC aggregates
✔ Early warning 6-12 months before imaging
Clinical Implications: From Prediction to Prevention
High-Risk “Sticky” Profiles
-
Loss of E-cadherin → 5x metastasis risk
-
Elevated CD44v6 → Bone metastasis predictor
-
Integrin α5β1+ → Lung tropism marker
Emerging Anti-Adhesion Therapies
| Drug Class | Target | Trial Phase |
|---|---|---|
| Selectin Inhibitors | E-selectin | II |
| Integrin Blockers | αvβ3/α5β1 | III |
| Cadherin Stabilizers | E-cadherin | I |
| Hyaluronidase | CD44 matrix | Approved (PEGPH20) |
Case Study: Breast Cancer Adhesion Profiling
Patient Profile:
-
48yo, ER+/HER2- invasive ductal carcinoma
-
Adhesion panel showed:
-
E-cadherin loss (80% cells)
-
High αvβ3 integrin
-
-
Prophylactic treatment:
-
Added integrin inhibitor to standard therapy
-
-
Outcome:
-
No metastasis at 3-year follow-up (vs 40% expected)
-
Why Choose Travel For Med for Metastasis Risk Testing?
We provide access to:
✔ Cutting-edge adhesion profiling
✔ Global oncology clinical trials
✔ Personalized prevention plans
✔ Second opinion services
Discover your cancer’s metastatic risk:
Contact Travel For Med Today for advanced testing options.
